A carregar...
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
BACKGROUND/AIMS: Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance may enhance dose and treatment...
Na minha lista:
| Publicado no: | Intest Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Korean Association for the Study of Intestinal Diseases
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7873400/ https://ncbi.nlm.nih.gov/pubmed/32635680 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2019.09167 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|